SNS-032 has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6.
For research use only. We do not sell to patients.
Name | SNS-032 ( BMS-387032 ) |
---|---|
Iupac Chemical Name | N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide |
Synonyms | SNS-032 ; BMS-387032 ; SNS032 ; SNS 032 ; BMS 387032 ; BMS387032 |
Molecular Formula | C17H24N4O2S2 |
Molecular Weight | 380.53 |
Smile | C(C)(C)(C)C1=CN=C(O1)CSC1=CN=C(S1)NC(=O)C1CCNCC1 |
InChiKey | OUSFTKFNBAZUKL-UHFFFAOYSA-N |
InChi | InChI=1S/C17H24N4O2S2/c1-17(2,3)12-8-19-13(23-12)10-24-14-9-20-16(25-14)21-15(22)11-4-6-18-7-5-11/h8-9,11,18H,4-7,10H2,1-3H3,(H,20,21,22) |
CAS Number | 345627-80-7 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | off-white solid |
---|---|
Purity | 98% |
Storage | 3 years -20ºCpowder |
Solubility | 5mg/ml in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |